H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This Phase II randomized, double-blinded, controlled study in up to 1000 males and
non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all
eligibility criteria is designed to provide data on an A/H7N9 vaccine made with HA antigen
derived from the influenza A/Shanghai/2/2013 virus.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)